The bioavailability is different. The side effects diverge. The pricing does not always favor the option you would expect.
The GLP-1 medication landscape is no longer injectable-only. In 2025 and 2026, several telehealth platforms began offering oral formulations alongside traditional subcutaneous injections, giving patients a choice that did not exist even two years ago.
But oral and injectable GLP-1s are not interchangeable in the way many marketing pages suggest. The bioavailability is different. The side effect profiles diverge. The pricing does not always favor the option you would expect. Here is an honest comparison — and which telehealth providers currently offer both.
Injectable semaglutide (Ozempic, Wegovy) and its compounded equivalents are administered subcutaneously, bypassing the digestive system entirely. Bioavailability is high — the drug reaches systemic circulation efficiently.
Oral semaglutide (Rybelsus) uses an absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to survive stomach acid and cross the intestinal wall. The bioavailability is roughly 1% compared to injectable, which is why oral doses are much higher in milligrams — 14mg oral vs 2.4mg injectable for comparable effect.
Newer oral formulations — including compounded oral semaglutide, sublingual tablets, and orally dissolving formats — take different approaches to this absorption challenge. Some use different enhancers. Others bypass gastric absorption entirely through sublingual delivery.
Both routes produce GI side effects — nausea, constipation, and appetite changes are common across all GLP-1 formulations. However, oral formulations tend to produce more upper GI symptoms (nausea, gastric discomfort) while injectable formulations are somewhat more associated with injection-site reactions and fatigue.
The dose titration curve also differs. Injectable patients typically start at 0.25mg and titrate up over weeks. Oral titration follows a different schedule, and some patients find the transition between dose steps rougher with oral formulations.
Not all telehealth platforms give you a real choice. Many are set up exclusively for injectable compounded semaglutide because the pharmacy relationships are simpler. Providers that genuinely offer both oral and injectable options as of May 9, 2026 include platforms with diversified pharmacy partnerships and broader formularies.
Injectable semaglutide with clinical titration support and ongoing monitoring.
From $297/mo · Pricing increases at 7.5mg+
Paid link · Affiliate disclosure
⚕️ Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Note: SHED pricing starts at $297–$299/mo but increases to $399/mo at doses of 7.5mg and above.
Compounded semaglutide program with direct intake and provider consultation.
From $239/mo (semaglutide)
Paid link · Affiliate disclosure
⚕️ Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
Weight loss and multi-specialty telehealth with pharmacy-direct fulfillment.
From $199/mo
Paid link · Affiliate disclosure
⚕️ Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
Oral GLP-1s are not necessarily cheaper than injectables — and in some cases, they cost more. Brand-name Rybelsus carries a list price comparable to Ozempic. Compounded oral formulations vary widely depending on the pharmacy and the delivery mechanism.
Injectable compounded semaglutide currently occupies the lowest price tier, with some platforms offering monthly rates under $150. Oral options through telehealth tend to start higher, partly because the compounding process is more complex and partly because the market is newer with fewer competing suppliers.
The decision between oral and injectable is not primarily about efficacy — clinical data shows comparable outcomes at equivalent doses. The real deciding factors are practical: Can you handle a weekly injection? Do you have a strong preference for oral medication? Are you willing to follow the strict fasting requirements for oral semaglutide (30 minutes before food or drink)?
For most patients starting GLP-1 therapy through telehealth in 2026, injectable compounded semaglutide remains the most accessible, most affordable, and best-studied option. Oral formulations are a legitimate alternative for patients with needle aversion or specific clinical circumstances — but they are not yet a default recommendation.
Affiliate Disclosure: Virtual Health Visits earns commissions when readers sign up through certain links. This does not influence our coverage, rankings, or editorial independence. We review providers with and without affiliate programs equally.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication or treatment program.